Lan Liang

Lan Liang

Auto-generated profile, based on publicly available information

Lan Liang

The First Clinical Medical School, Shaanxi University of Chinese Medicine, Xianyang, People’s Republic of China

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 May 2017 in Oncotarget
Verified
Journal Article
Open access
YLYan-Rong Liu
Yan-Rong Liu
LLLan Liang
Lan Liang
JZJian Min Zhao
Jian Min Zhao
Yang ZhangYang Zhang
Yang Zhang
ZMZhang Min
Zhang Min
CYCheng Yang
Cheng Yang
Twist1 confers multidrug resistance in colon cancer through upregulation of ATP-binding cassette transporters Twist1 confers multidrug resistance in colon cancer through upregulation of ATP-binding cassette transporters

1 December 2024 in Drug Design, Development and Therapy
Verified
Journal Article
Open access
PDF file
LLLan Liang
Lan Liang
CHChenming He
Chenming He
XHXue Han
Xue Han
JLJia Liu
Jia Liu
LYLiuhong Yang
Liuhong Yang
JLJie Lin
Jie Lin
Background: Precancerous lesions of gastric cancer (PLGC) represent critical stages in gastric cancer progression, with a high risk of malignancy. Current treatments, such as Helicobacter pylori eradication, show limited efficacy in reversing precancerous molecular changes. Zuojin Pill (ZJP), a traditional Chinese medicine, has demonstrated potential for treating digestive disorders and may offer a promising approach for PLGC intervention. Objective: This study aims to investigate the therapeutic effects and mechanisms of ZJP in treating PLGC, focusing on its active components, target pathways, and molecular interactions. By using advanced analytical techniques, we provide a scientific foundation for ZJP’s potential application in early gastric cancer intervention. Methods: Using ultra-high performance liquid chromatography-quadrupole orbitrap high-resolution mass spectrometry (UPLC-Q-Orbitrap HRMS), we identified active components in ZJP. A network pharmacology approach was then applied to construct a “ZJP-compound-target-disease” network. Molecular docking and molecular dynamics simulations were conducted to analyze the stability and interactions of the main active components of ZJP with core protein targets in PLGC. Animal experiments were used to validate significant targets and pathways in vivo. Results: Tangeritin, Isorhamnetin, Caffeic Acid, Azelaic Acid, and Adenosine were identified as the main active components of ZJP in the treatment of PLGC, with key targets including PIK3R1, MAPK3, SRC, JAK2, STAT3, and PIK3CA. Molecular docking and molecular dynamics simulations further confirmed the relationship between compounds and target proteins. The potential molecular mechanism of ZJP predicted by network pharmacology analysis was confirmed in PLGC rats. ZJP downregulated IL-6, TNF-α, c-myc, p-MEK1 and p-ERK1/2, effectively reversing the progression of PLGC. Conclusion: ZJP can reverse MNNG-induced PLGC, potentially through inhibition of the MEK/ERK/c-myc pathway and regulation of cellular proliferation and apoptosis.